Search Result

Results for "

GSK3A+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Amyloid-β (8) Apoptosis (6) Autophagy (3) Bcl-2 Family (1) c-Myc (1) Caspase (1) CDK (5) Cholinesterase (ChE) (1) Cytochrome P450 (1) Dopamine Receptor (1) Drug Intermediate (1) DYRK (1) GSK-3 (82) HIV (1) HSV (1) Isotope-Labeled Compounds (2) Lipoxygenase (1) Microtubule/Tubulin (1) Mitophagy (1) NF-κB (6) P-glycoprotein (1) p38 MAPK (1) Phosphodiesterase (PDE) (2) Pim (1) PKA (1) PKC (5) PROTACs (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) ROS Kinase (1) Tau Protein (7) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (32) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (13) Metabolic Disease (28) Neurological Disease (51)

By Targets:

AAK1 (1)

Amyloid-β (8)

Apoptosis (6)

Autophagy (3)

Bcl-2 Family (1)

c-Myc (1)

Caspase (1)

CDK (5)

Cholinesterase (ChE) (1)

Cytochrome P450 (1)

Dopamine Receptor (1)

Drug Intermediate (1)

DYRK (1)

GSK-3 (82)

HIV (1)

HSV (1)

Isotope-Labeled Compounds (2)

Lipoxygenase (1)

Microtubule/Tubulin (1)

Mitophagy (1)

NF-κB (6)

P-glycoprotein (1)

p38 MAPK (1)

Phosphodiesterase (PDE) (2)

Pim (1)

PKA (1)

PKC (5)

PROTACs (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (2)

ROS Kinase (1)

Tau Protein (7)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (32)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (13)

Metabolic Disease (28)

Neurological Disease (51)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126144A

*(E/Z)-GSK-3β inhibitor* 1**	GSK-3	Metabolic Disease
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM .

HY-112392

GSK-3 Inhibitor XIII	GSK-3	Cancer
GSK-3 Inhibitor XIII is a potent and ATP-competitive *GSK-3* inhibitor with a K_i of 24 nM .

HY-130795

*GSK-3β inhibitor* 2** 1 Publications Verification	GSK-3	Neurological Disease
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active *GSK-3β* inhibitor with an IC₅₀ of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease .

HY-112388

*GSK-3b Inhibitor* XI** 1 Publications Verification	GSK-3	Neurological Disease Metabolic Disease
GSK-3b Inhibitor XI (Compound 33) is a potent and selective *GSK3β* inhibitor, with a K_i value of 25 nM. GSK-3b Inhibitor XI increases glycogen synthase (GS) activity. GSK-3b Inhibitor XI can be used for research on type 2 diabetes and Alzheimer’s disease .

HY-164907

*GSK-3β inhibitor* 22**	GSK-3	Neurological Disease
GSK-3β inhibitor 22 (compound 20o) is a *GSK-3β* inhibitor with an IC₅₀ of 3.1 nM. GSK-3β inhibitor 22 has the potential of the study of Alzheimer's disease .

HY-147134

*GSK-3β inhibitor* 10**	GSK-3	Neurological Disease
GSK-3β inhibitor 10 (compound 14a) is a highly potent *GSK-3β* inhibitor with an IC₅₀ value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease .

HY-126201

GSK-3 inhibitor 7	GSK-3	Neurological Disease
GSK-3 inhibitor 7 (compound 22) is a glycogen synthase kinase-3 (GSK-3) inhibitor. GSK-3 inhibitor 7 can be used in nervous system research .

HY-169024

*GSK-3β inhibitor* 19**	GSK-3	Neurological Disease Inflammation/Immunology
GSK-3β inhibitor 19 (compound 36) is a *GSK-3β* inhibitor, with IC₅₀ of 70 nM. GSK-3β inhibitor 19 can be used in anti-inflammatory and Alzheimer's disease related research .

HY-169602

*GSK-3β inhibitor* 26**	GSK-3	Neurological Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 26 (Compound D14) is a *GSK-3β* inhibitor with an IC₅₀ of 18.23 μM. GSK-3β inhibitor 26 can be used in the research of cancer, inflammation and neurodegenerative diseases .

HY-143260

*GSK-3β inhibitor* 6**	GSK-3	Metabolic Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 6 is a potent *GSK-3β* inhibitor with an IC₅₀ value of 24.4 μM. GSK-3β inhibitor 6 shows high hepatocyte glucose uptake (38%). GSK-3β inhibitor 6 can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .

HY-149542

*GSK-3β inhibitor* 15**	Tau Protein Apoptosis GSK-3	Neurological Disease
GSK-3β inhibitor 15 (Compound 54) is a *GSK-3β* inhibitor (IC₅₀: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ_1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ_1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .

HY-168857

*GSK-3β inhibitor* 24**	GSK-3 Tau Protein β-catenin	Neurological Disease
GSK-3β inhibitor 24 (Compound 41) is a potent *GSK-3β* inhibitor with an IC₅₀ of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of tau protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects .

HY-174272

*GSK-3β inhibitor* 27**	GSK-3 Amyloid-β	Neurological Disease
GSK-3β inhibitor 27 (Compound 1c) is a reversible and competitive *GSK-3β* inhibitor with an IC₅₀ value of 2.2 μM. GSK-3β inhibitor 27 inhibits tau hyperphosphorylation, reduces Aβ protein aggregation and possesses metal chelation and neuroprotective potential. GSK-3β inhibitor 27 is promising for research of neurodegenerative diseases (such as Alzheimer’s disease) .

HY-14679

*GSK3β inhibitor* II**	GSK-3	Neurological Disease
GSK3β inhibitor II is an inhibitor of *GSK3β. GSK3β inhibitor* II can be used for research of Alzheimer’s disease (AD) .

HY-148132

*GSK-3β inhibitor* 11**	GSK-3	Neurological Disease
GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC₅₀=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research .

HY-153760

*GSK-3β inhibitor* 14**	GSK-3	Neurological Disease Metabolic Disease
GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak *GSK-3β* inhibitor (IC₅₀ >100 μM) .

HY-168079

*GSK-3β inhibitor* 21**	GSK-3 Tau Protein	Neurological Disease Inflammation/Immunology
GSK-3β inhibitor 21 (compound 44) is an ATP-competitive *GSK-3β* inhibitor (IC₅₀=6.06 μM) with anti-amyloid aggregation and tau phosphorylation inhibitory activities. GSK-3β inhibitor 21 can be used in the study of Alzheimer's disease .

HY-161458

*GSK-3β inhibitor* 16**	GSK-3 Tau Protein	Neurological Disease
GSK-3β inhibitor 16 (compound 7c) is a *GSK-3β* inhibitor with the IC₅₀ of 4.68 nM. GSK-3β inhibitor 16 decreases Tau hyperphosphorylated aggregate and alleviates cognitive impairments in the Scopolamin (HY-N0296)-induced model in mice .

HY-163748

*GSK-3β inhibitor* 17**	GSK-3	Inflammation/Immunology
GSK-3β inhibitor 17 (compound 5 n) is a potent *GSK-3β* inhibitor. GSK-3β inhibitor 17 decreases cisplatin (HY-17394) induced p-p65, KIM-1 protein and mRNA expression. GSK-3β inhibitor 17 decreases cisplatin induced TNF-α, IL-1β, IL-6 and MCP-1 mRNA expression. GSK-3β inhibitor 17 shows anti-inflammation effect and has the potential for the research of acute kidney injury .

HY-143261

*GSK-3β inhibitor* 7**	GSK-3	Metabolic Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 7 is a *GSK-3β* inhibitor with an IC₅₀ value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .

HY-175850

GSK-3β-IN-28	GSK-3 Apoptosis NF-κB c-Myc	Cancer
GSK-3β inhibitor 28 is selective and non-competitivea glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC₅₀ of 14.82 nM. GSK-3β inhibitor 28 can upregulate the expression level of phosphorylated GSK-3β and downregulate the expression of p-NF-κB, P65, C-myc and Cyclin D1. GSK-3β inhibitor 28 can induce cells apoptosis, G1 phase arrest and inhibit migration. GSK-3β inhibitor 28 can be used for the research of cancer, such as colorectal cancer .

HY-149054

*GSK-3β inhibitor* 13**	GSK-3 Tau Protein AAK1 Pim PKC	Neurological Disease
GSK-3β inhibitor 13 (compound 47) is an orally active and potent *GSK-3β* inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits *GSK-3β* and *GSK-3α* with IC₅₀s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC₅₀=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease .

HY-162722

GSK-3 inhibitor 6	GSK-3	Others
GSK-3 inhibitor 6 (2) is a CNS penetrated *GSK-3* inhibitor, with IC₅₀ values of 29 nM and 24 nM for GSK-3α and GSK-3β, respectively .

HY-148133

*GSK-3β inhibitor* 12**	GSK-3	Neurological Disease
GSK-3β inhibitor 12 (compound 15) is an inhibitor of *GSK-3β. GSK-3β inhibitor* 12 inhibits 49.11% and 37.11% activity of 25 μM and 50 μM GSK-3β, respectively. GSK-3β inhibitor 12 can be used for the research of neurodegenerative diseases .

HY-13973A

GSK-3 inhibitor 1 1 Publications Verification	GSK-3	Metabolic Disease
GSK-3 inhibitor 1 (compound core 3) is a *GSK-3* inhibitor that induces stem/progenitor cell self-renewal (e.g. induces stem/progenitor cell proliferation while maintaining the ability to differentiate into tissue cells in the progeny) .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of *GSK-3, CDK2, and CDK5, with IC₅₀* values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-126144

*GSK-3β inhibitor* 1** 3 Publications Verification	GSK-3	Metabolic Disease Cancer
GSK-3β inhibitor 1 (compound 3a) inhibits *GSK-3β* with an IC₅₀ of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats .

HY-154851

GSK-3 inhibitor 3	GSK-3 CDK Tau Protein	Neurological Disease
GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of *GSK-3, with IC₅₀s of 0.35 nM and 0.25 nM for GSK-3α* and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC₅₀ of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research .

HY-120902

*GSK-3β inhibitor* 8**	Wnt GSK-3	Inflammation/Immunology
GSK-3β inhibitor 8, a thiophenacil derivative, is an effective and selective inhibitor of *GSK-3β* (IC₅₀=64 nM). GSK-3β inhibitor 8 negatively regulated Wnt signaling pathway and stimulated β cell proliferation .

HY-141480

*GSK-3β inhibitor* 3** 1 Publications Verification	GSK-3 Apoptosis	Cancer
GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC₅₀ of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia .

HY-170491

*GSK-3β inhibitor* 23**	GSK-3	Infection Neurological Disease
GSK-3β inhibitor 23 (Compound 11726169) is the inhibitor for glycogen synthase kinase-3, that inhibits *GSK-3β* and *GSK-3α* with IC₅₀ of 12.1 nM and 18.8 nM. GSK-3β inhibitor 23 exhibits antiviral activity against HIV 1. GSK-3β inhibitor 23 exhibits good metabolic stablility in mouse/human liver microsomes and plasma, but poor Caco-2 permeability (which predicts low oral bioavailability) .

HY-117194

18BIOder	HIV GSK-3	Infection
18BIOder is a neuroprotective *GSK-3*β inhibitor, highly selectively inhibiting HIV-1 .

HY-10512

AR-A014418 15+ Cited Publications AR 0133418; GSK 3β inhibitor VIII; AR 014418	GSK-3	Metabolic Disease Cancer
AR-A014418 is a potent, selective and ATP-competitive *GSK3β* inhibitor (IC₅₀=104 nM; K_i=38 nM) .

HY-162638

*GSK-3β inhibitor* 18**	GSK-3	Neurological Disease
GSK-3β inhibitor 18 (compound 2) is a potent inhibitor of *GSK-3β, with the IC₅₀* of 0.0021 μM .

HY-162913

*GSK-3β inhibitor* 20**	GSK-3	Neurological Disease
GSK-3β inhibitor 20 (compound 3A) is an potent inhibitor of GSK-3β with an IC₅₀ value of 74.4 nM .

HY-107530

3F8	GSK-3	Cardiovascular Disease Metabolic Disease Cancer
3F8 is a potent and selective *GSK-3β* inhibitor that could be useful as new reagent and potential therapeutic candidate for GSK3 related diseases .

HY-12074

Cazpaullone	GSK-3	Metabolic Disease
Cazpaullone is a glycogen synthase kinase-3 (GSK-3) inhibitor. Cazpaullone can activate pancreatic beta cell protection and replication. Cazpaullone can be used for the research of diabetes .

HY-Q48328

GSK3-IN-1	GSK-3	Metabolic Disease
GSK3-IN-1 (compound 11) is a *GSK-3* inhibitor with an IC₅₀ value of 12 μM. GSK3-IN-1 can be used in the research of diabetes .

HY-12012

SB 216763 Maximum Cited Publications 40 Publications Verification	GSK-3 Autophagy	Neurological Disease Cancer
SB 216763 is potent, selective and ATP-competitive *GSK-3* inhibitor with IC₅₀s of 34.3 nM for both GSK-3α and GSK-3β.

HY-100207

CP21R7 5+ Cited Publications CP21	GSK-3	Cancer
CP21R7 is potent *GSK-3β* inhibitor, with an IC₅₀ of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC₅₀ of 1900 nM.

HY-15356

BIO-acetoxime 2 Publications Verification BIA	GSK-3 Apoptosis HSV	Infection Neurological Disease Inflammation/Immunology
BIO-acetoxime (BIA) is a potent and selective *GSK-3* inhibitor, with IC₅₀s of both 10 nM for GSK-3α/β. BIO-acetoxime has anticonvulsant and anti-infection activity.

HY-169606

*GSK-3β inhibitor* 25**	GSK-3	Neurological Disease Metabolic Disease
GSK-3β inhibitor 25 (Compound 6h) exhibits a weak inhibitory activity against *GSK-3β* wih an IC₅₀>100 μM .

HY-30236

5-Bromoindole	Drug Intermediate	Cancer
5-Bromoindole is a chemical intermediate. 5-Bromoindole derivatives have anticancer activity against breast cancer. 5-Bromoindole can be used to synthesize GSK-3 inhibitors and anticancer active molecules .

HY-15761

AZD2858 5+ Cited Publications	GSK-3	Neurological Disease
AZD2858 is a potent, orally active *GSK-3* inhibitor, with IC₅₀s of 0.9 and 5 nM for *GSK-3α* and *GSK-3β*, respectively, used in the research of fracture healing.

HY-169632

GSK3β-IN-1	GSK-3	Neurological Disease
GSK3β-IN-1 (compound 1) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC₅₀=65 nM), which can be used in the study of Alzheimer's disease .

HY-13867A

Bisindolylmaleimide I hydrochloride 35+ Cited Publications GF109203X hydrochloride; Go 6850 hydrochloride	PKC GSK-3	Metabolic Disease Cancer
Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor (IC₅₀ of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I hydrochloride is also a *GSK-3* inhibitor ^[3].

HY-14872

Tideglusib 5+ Cited Publications NP031112	GSK-3	Neurological Disease
Tideglusib (NP031112) is an irreversible *GSK-3* inhibitor with IC₅₀s of 5 nM and 60 nM for GSK-3β ^WT (1 h preincubation) and GSK-3β ^C199A (1 h preincubation), respectively.

HY-111055

BIP-135	GSK-3	Neurological Disease
BIP-135 is a potent and selective ATP-competitive *GSK-3* inhibitor, with IC₅₀s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect .

HY-13867

Bisindolylmaleimide I 35+ Cited Publications GF109203X; Go 6850	PKC GSK-3	Metabolic Disease Cancer
Bisindolylmaleimide I (GF109203X) is a cell-permeable and reversible PKC inhibitor (IC₅₀ of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I is also a *GSK-3* inhibitor ^[3].

HY-124607B

BRD3731 2 Publications Verification	GSK-3	Neurological Disease Metabolic Disease
BRD3731 is a selective *GSK3β* inhibitor, with IC₅₀s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders .

Cat. No.	Product Name	Target	Research Area

HY-P1173

L803-mts Myristoylated L 803; GSK-3β Inhibitor XIII	GSK-3 Amyloid-β	Neurological Disease
L803-mts (Myristoylated L 803) is a selective and substrate-competitive *GSK-3* peptide inhibitor (IC₅₀: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .

HY-P1385

TCS 183	GSK-3 p38 MAPK	Neurological Disease
TCS 183, a peptide, is a *GSK-3β* inhibitor. TCS 183 blocks GSK-3β autoinhibition and decreases the level of AMPK phosphorylation. TCS 183 can be used for neuropathological diseases, particularly Alzheimer’s disease, research .

Cat. No.	Product Name	Chemical Structure

HY-10512S

AR-A014418-d3
AR-A014418-d₃ is the deuterium labeled AR-A014418. AR-A014418 is a potent, selective, and ATP-competitive GSK3β inhibitor (IC₅₀=104 nM; K_i=38 nM) .

HY-B1619S

Cromolyn-d5

Cromolyn-d₅ (Cromoglycate-d₅) is the deuterium labeled Cromolyn (HY-B1619). Cromolyn (Cromoglycate) is an orally active GSK-3β inhibitor with an IC₅₀ of 2.0 μM. Cromolyn is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn can be used in the research of bronchial asthma. In addition, Cromolyn has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: